Core Viewpoint - Xiansheng Pharmaceutical (02096) has initiated a Phase II clinical trial for its IL-2mu-Fc SIM0278 injection for moderate to severe atopic dermatitis in China, which has positively impacted its stock price, increasing by 5.83% to HKD 13.8 [1] Group 1: Clinical Research - The Phase II clinical trial for SIM0278 is a randomized, double-blind, placebo-controlled, multicenter study aimed at evaluating the efficacy, safety, and pharmacokinetics of continuous subcutaneous administration in subjects with moderate to severe atopic dermatitis [1] - The first patient has been dosed at Hangzhou First People's Hospital, marking a significant milestone in the clinical development of the drug [1] Group 2: Financial Outlook - Huatai Securities reported that Xiansheng Pharmaceutical reiterated its commitment to commercializing multiple innovative pipelines, which are expected to drive revenue growth alongside mature products [1] - The company is initiating the overseas market entry of several early-stage innovative product lines, including ADC and dual antibodies, which have global market potential [1] - The firm is optimistic about the rapid growth of the company's revenue and net profit attributable to shareholders from 2025 to 2027, supported by the commercialization of its innovation system and expansion into overseas markets [1]

Core Viewpoint - The company announced the initiation of a Phase II clinical trial in China for its proprietary IL-2 mu-Fc injection, SIM0278, in collaboration with Almirall, targeting moderate to severe atopic dermatitis [1] Group 1 - The clinical trial has officially started at Hangzhou First People's Hospital, marking a significant step in the development of SIM0278 [1] - SIM0278 is a regulatory T cell (Treg) preferential IL-2 mutant fusion protein, indicating its specialized mechanism of action [1]